Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].



1st September 2013 - New research


PLoS One [2013] 8 (7) : e69738 (C.Q.Zhou, S.S.Li, Z.M.Chen, F.Q.Li, P.Lei, G.G.Peng) Complete abstract

A systematic review has been carried out on the clinical trials of rotigotine transdermal patch, in order to evaluate the efficacy, tolerability, and safety in Parkinson's Disease. Rotigotine transdermal patch is marketed as Neupro. Neupro is a transdermal system that provides continuous delivery of rotigotine, which is a dopamine agonist, for 24 hours following application to intact skin. For more information go to Neupro.

The use of rotigotine resulted in greater improvements in Parkinson's Disease symptom scores (the UPDRS) concerning the activities of daily living score, motor score, and the activities of daily living and motor subtotal score. However, rotigotine was associated with a significantly higher rate of withdrawals due to adverse events, and higher rates of application site reactions, vomiting, and dyskinesia. No differences were found in the relative risks of headache, constipation, back pain, diarrhea, or serious adverse events.  For a printable version of this article click here.
or more news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

















2006-2013  Viartis
2015-01-04 15:36:23
[email protected]